VU-0152099

VU-0152099
[[File:|frameless|220px|alt=|Chemical structure of VU-0152099]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

VU-0152099 is a chemical compound that acts as a selective positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4). It is primarily used in scientific research to study the role of mGluR4 in the central nervous system and its potential therapeutic applications.

Pharmacology

VU-0152099 enhances the activity of mGluR4, a receptor that is part of the group III metabotropic glutamate receptors. These receptors are G-protein coupled receptors that modulate neurotransmission in the brain. mGluR4 is predominantly expressed in the cerebellum, thalamus, and hippocampus, and is involved in the regulation of glutamate release.

The modulation of mGluR4 by VU-0152099 has been shown to have potential therapeutic effects in models of Parkinson's disease, anxiety, and pain. By enhancing mGluR4 activity, VU-0152099 may help to reduce excessive glutamate release, which is implicated in neurodegenerative diseases and excitotoxicity.

Mechanism of Action

VU-0152099 binds to an allosteric site on the mGluR4 receptor, distinct from the orthosteric site where glutamate binds. This binding increases the receptor's response to glutamate, thereby potentiating its signaling pathways. The positive allosteric modulation of mGluR4 can lead to decreased release of excitatory neurotransmitters, providing a neuroprotective effect.

Research Applications

VU-0152099 is used in preclinical research to explore the therapeutic potential of mGluR4 modulation. Studies have demonstrated its efficacy in animal models of Parkinson's disease, where it helps to alleviate motor symptoms by modulating basal ganglia circuits. Additionally, its anxiolytic and analgesic properties are being investigated for potential use in treating anxiety disorders and chronic pain.

Safety and Toxicology

As a research compound, VU-0152099 is not approved for clinical use in humans. Its safety profile is primarily characterized in animal studies, where it has shown a favorable safety margin. However, further studies are needed to fully understand its pharmacokinetics and potential side effects.

Also see

• Metabotropic glutamate receptor
• Allosteric modulator
• Parkinson's disease
• Neurotransmitter